These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35112378)

  • 1. Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain.
    Shoji S; Suzuki A; Gaitonde P; Cai CH; Marshall S
    Br J Clin Pharmacol; 2022 Jul; 88(7):3321-3334. PubMed ID: 35112378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.
    Jonsson EN; Xie R; Marshall SF; Arends RH
    Br J Clin Pharmacol; 2016 Apr; 81(4):688-99. PubMed ID: 26613544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor.
    Shoji S; Suzuki A; Nouri P; Cai CH; Gaitonde P; Marshall S
    CPT Pharmacometrics Syst Pharmacol; 2023 Sep; 12(9):1358-1370. PubMed ID: 37470295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tanezumab for the treatment of osteoarthritis pain.
    Gondal FR; Bilal J; Kent Kwoh C
    Drugs Today (Barc); 2022 Apr; 58(4):187-200. PubMed ID: 35412532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.
    Brown MT; Cornblath DR; Koltzenburg M; Gorson KC; Hickman A; Pixton GC; Gaitonde P; Viktrup L; West CR
    Clin Drug Investig; 2023 Jul; 43(7):551-563. PubMed ID: 37460782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tanezumab in the treatment of chronic musculoskeletal conditions.
    Jayabalan P; Schnitzer TJ
    Expert Opin Biol Ther; 2017 Feb; 17(2):245-254. PubMed ID: 27936977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis.
    Leite VF; Buehler AM; El Abd O; Benyamin RM; Pimentel DC; Chen J; Hsing WT; Mazloomdoost D; Amadera JE
    Pain Physician; 2014; 17(1):E45-60. PubMed ID: 24452657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain.
    Gimbel JS; Kivitz AJ; Bramson C; Nemeth MA; Keller DS; Brown MT; West CR; Verburg KM
    Pain; 2014 Sep; 155(9):1793-1801. PubMed ID: 24937440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tanezumab in the treatment of chronic low back pain.
    Katz N; Borenstein DG; Birbara C; Bramson C; Nemeth MA; Smith MD; Brown MT
    Pain; 2011 Oct; 152(10):2248-2258. PubMed ID: 21696889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain.
    Kivitz AJ; Gimbel JS; Bramson C; Nemeth MA; Keller DS; Brown MT; West CR; Verburg KM
    Pain; 2013 Jul; 154(7):1009-21. PubMed ID: 23628600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration.
    Losina E; Michl G; Collins JE; Hunter DJ; Jordan JM; Yelin E; Paltiel AD; Katz JN
    Osteoarthritis Cartilage; 2016 May; 24(5):776-85. PubMed ID: 26746146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab.
    Carrino JA; McAlindon TE; Schnitzer TJ; Guermazi A; Hochberg MC; Conaghan PG; Brown MT; Burr A; Fountaine RJ; Pixton GC; Viktrup L; Verburg KM; West CR
    Osteoarthritis Cartilage; 2023 Dec; 31(12):1612-1626. PubMed ID: 37652258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different Dosage Regimens of Tanezumab for the Treatment of Chronic Low Back Pain: A Meta-analysis of Randomized Controlled Trials.
    Lian J; Wang J; Li X; Yang S; Li H; Zhong Y; Gao H; Chen G
    Clin Neuropharmacol; 2023 Jan-Feb 01; 46(1):6-16. PubMed ID: 36542785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.
    Spierings ELH; Fidelholtz J; Wolfram G; Smith MD; Brown MT; West CR
    Pain; 2013 Sep; 154(9):1603-1612. PubMed ID: 23707270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.
    Hochberg MC; Tive LA; Abramson SB; Vignon E; Verburg KM; West CR; Smith MD; Hungerford DS
    Arthritis Rheumatol; 2016 Feb; 68(2):382-91. PubMed ID: 26554876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
    Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
    Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
    Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment.
    Brown MT; Herrmann DN; Goldstein M; Burr AM; Smith MD; West CR; Verburg KM; Dyck PJ
    J Neurol Sci; 2014 Oct; 345(1-2):139-47. PubMed ID: 25073573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.